FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
On January 17, 2025, the Food and Drug Administration approved datopotamab deruxtecan-dlnk, a Trop-2-directed antibody…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
PICH protein as key player in preventing chromosome breakage linked to cancer
Researchers at The University of Hong Kong (HKU) have made an exciting discovery about how…
Time to boost cancer vaccine work, declare UK researchers
UK oncology researchers have come together to write the first-ever national thought leadership strategy report…
Epigenetic ageing and DNA-methylation as tumour markers for breast cancer
A new research paper was published in the journal Ageing titled “DNA-methylation age and accelerated epigenetic…
European Commission expands dostarlimab plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer
GSK plc announced today that the European Commission has approved dostarlimab in combination with chemotherapy…
European Commission approves lazertinib in combination with amivantamab for the first-line treatment of patients with EGFR-mutated advanced NSCLC
Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC)…
Early diagnosis of bladder cancer, now conveniently at home
Bladder cancer has a cure rate of over 90% when detected early, but it has…
Researchers develop biomarker algorithm for noninvasive detection of Barrett’s oesophagus and oesophageal cancer
By studying biomarkers known to be involved in gastrointestinal cancers, researchers at the Johns Hopkins…
Deep learning model helps detect lung tumours on CT
A new deep learning model shows promise in detecting and segmenting lung tumours, according to…
First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer
Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm…